S. Takafuji, Y. Miyakuni, K. Hirai
Mar 1, 2001
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
International Archives of Allergy and Immunology
Abstract
Background: Seratrodast is one of the antiallergic drugs and causes antagonism not only to thromboxane A2 but also to prostaglandin D2 (PGD2). It has been reported that PGD2 increases cytosolic free calcium concentration ([Ca2+]i) in human eosinophils. In this study, we have examined the effect of seratrodast on eosinophil cationic protein (ECP) release and changes of [Ca2+]i in human eosinophils induced by PGD2. Methods: Eosinophils from healthy donors were incubated with or without IL-3 for 10 min after incubation with or without seratrodast for 15 min. Then, they were stimulated with PGD2 for 20 min after incubation with cytochalasin B for 10 min. Results: PGD2 induced significant ECP release in IL-3-primed eosinophils. This ECP release was significantly inhibited by seratrodast. Seratrodast had no effect on ECP release induced by PAF in IL-3-primed eosinophils. Furthermore, pretreatment with seratrodast inhibited cytosolic calcium increase induced by PGD2 in human eosinophils, and it had no effect on that induced by PAF. Conclusions: This study shows that PGD2 induces ECP release in IL-3-primed eosinophils and that seratrodast suppresses its effect. This inhibition by seratrodast may contribute to its clinical efficacy in the treatment of bronchial asthma.